UniversityLibraryCurrent studentsStaff intranet
University of Sydney
University of Sydney
View Item 
  • Sydney eScholarship Home
  • Postgraduate Theses
  • Sydney Digital Theses (Open Access)
  • View Item
  • Sydney eScholarship Home
  • Postgraduate Theses
  • Sydney Digital Theses (Open Access)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Molecular Markers of Pancreatic β-cell Death

Thumbnail
View/Open
Thesis (PDF, 6.88MB)
Date
2017-04-24
Author
Farr, Ryan
Metadata
Show full item record
Abstract
Abstract Loss of insulin-producing β-cells is central to the development of Type 1 diabetes (T1D). Currently, we lack diagnostic tools to quantitate this β-cell loss. Non-protein coding RNAs called microRNAs (miRNAs/miRs) play an important role in islet development and function. Recent detection of miRNAs in peripheral circulation, has renewed interest in microRNA biomarkers of diabetes. Comparably, circulating insulin cell-free (cf)DNA has been proposed as a direct biomarker of β-cell death. DNA methylation studies have identified specific sites within DNA that are unmethylated in β-cells but methylated in other cell types, thus providing a handle to discriminate between cfDNA from β-/non-β-cells. Previous research carried out in the Hardikar lab identified a signature of 20 miRNAs (the ‘RAPID’ signature) with potential as a biomarker of β-cell death. The RAPID signature was revised to accommodate other microRNAs finally constituting a panel of 50 microRNAs (PREDICT T1D panel). An analysis of these 50 miRNAs, as well as insulin cfDNA in serum/plasma from individuals before, during and after clinical diagnosis of T1D is presented. Human islet cell death assays using sodium nitroprusside exposure identified a subset of 27 miRNAs and insulin cfDNA associated with islet cell stress/death. Non-obese diabetic mice (N=32) were found to have elevated candidate miRNAs prior to immune infiltration and glycaemic dysfunction. This trend was also noted in the human progression to T1D; 26 miRNAs were elevated in (N=19) high-risk individuals and those at diagnosis (N=199) but decreased within 6-weeks after diagnosis. Furthermore, candidate miRNAs exhibited differential abundance with disease duration, residual C-peptide, and microvascular complications in 180 subjects with prolonged T1D. At diagnosis, miRNAs and cfDNA associated with GAD III autoantibody titres (N=167 P-values range from 0.044 to <0.0001) and HbA1c levels (N=187, P-values range from 0.047 to 0.00095). Such biomarkers may inform medical researchers as to how to predict the development of T1D, monitor response to interventions such as islet transplantation, vaccines & drugs aiming to retard β-cell loss. In basic research, such an assay may help to select treatments to block β-cell death and guide the development of new treatments to lessen the burden of diabetes.
URI
http://hdl.handle.net/2123/17308
Collections
  • Sydney Digital Theses (Open Access) [4718]

Browse

All of Sydney eScholarshipCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

Most Popular ItemsStatistics by CountryMost Popular Authors

Links

University homeLibraryCurrent studentsStaff intranet

Repository

  • About us
  • FAQ
  • Policies & guidelines
  • Email us
  • Non-UniKey login
Leadership for good starts here

Media

  • News
  • Find an expert
  • Media contacts

Student links

  • Log in to University systems
  • Study dates
  • Student handbooks
  • Timetables
  • Library

About us

  • Our world rankings
  • Faculties and schools
  • Centres and institutes
  • Campus locations
  • Maps and locations

Connect

  • Contact us
  • Find a staff member
  • Careers at Sydney
  • Events
  • Emergencies and personal safety
Inspired: Campaign to support the University of SydneyGroup of Eight
Disclaimer
Privacy
Accessibility
Website feedback
ABN: 15 211 513 464
CRICOS Number: 00026A
Disclaimer
Privacy
Accessibility
Website feedback
ABN: 15 211 513 464
CRICOS Number: 00026A